- LOGIN
- MemberShip
- 2025-12-23 11:37:52
- Company
- Daewon’s Pelubi enters Indonesia with a KRW 4 bil deal
- by Chon, Seung-Hyun Sep 26, 2023 05:49am
- On the 25th, Daewon Pharmaceutical announced that its nonsteroidal anti-inflammatory drug, ‘Pelubi CR Tab’ has entered the Indonesian market. Pic of Pelubi series Daewon Pharmaceutical signed an exclusive export agreement with its Indonesian partner, PT. Interbat Pharmaceutical Industry, to export its finished Pelubi CR Tablet products to Indonesia. The 5-year deal is worth a total of USD 3 million (KRW 4 billion). Pelubi CR tablet is an improved version of Daewon’s new drug ‘Pelubi’ that offers improved convenience in administration. After being released in 2015 as an anti-inflammatory analgesic in 2012, its prescription area has been expanded, adding various indications such as post-traumatic pain and primary menstrual pain into the areas of chronic pain and acute pain. Daewon Pharmaceutical said, “Our Pelubi series has grown into a mega-brand product that posts annual sales of approximately KRW 40 billion, and has achieved the highest prescription volume among NSAIDs in Korea.” Indonesia is a country with a high demand for pharmaceuticals in Asia, accounting for approximately 27% of the entire ASEAN market. Its pharmaceutical market size amounts to approximately USD 3 billion (approximately KRW 4.022 trillion) in 2021. Pelubi was released in Russia early last year after 2 years of local clinical trials and on-site inspections. Daewon Pharmaceutical is planning to sign new export contracts with the Philippines and Mexico in H2, using its entry into the Russian and Indonesian markets as momentum. The company is waiting to complete product registration in Vietnam. Daewon Pharmaceutical plans to accelerate its expansion into overseas markets, focusing on the Eurasian Economic Union (EAEU) which includes Russia and Kazakhstan, as well as Central and South America, and Southeast Asia. In-Hwan Baek, CEO of Daewon Pharmaceutical, said, “As Pelubi was classified as a new drug in Indonesia, the export holds significance in introducing a Korean new drug to the foreign market. We expect this to significantly contribute to expanding our presence in the Asian and global market.”
- Company
- Luxturna can be prescribed at general hospitals
- by Eo, Yun-Ho Sep 26, 2023 05:49am
- Luxturna, a one-shot retina treatment, can be prescribed at general hospitals. According to related industries, Luxturna, a treatment for Inherited Retinal Dystrophy, has passed the drug committee of medical institutions such as Seoul National University Hospital. Luxturna is currently in the process of registering for insurance benefits and is beginning to create a prescription environment. This drug passed HIRA on the 7th and is about to negotiate the price with NHIS. Discussions on reimbursement for Luxturna, which is an expensive drug and targets a very small number of patients, were difficult. An application for benefits was submitted in September 2021, but there has been no significant progress in the registration process and only recently produced results. Although it has passed the evaluation committee, it remains to be seen whether drug price negotiations can be concluded smoothly. Luxturna restores the function of the deficient or defective RPE65 gene, which is one of the causes of IRD, by replacing it with a normal gene with just one administration. This means that fundamental treatment of the disease is possible. This drug was designated by the U.S. FDA as a Breakthrough Therapy in 2014, an Orphan Drug in 2016, and a Priority Review in 2017, and it also obtained expedited approval in 2017. Meanwhile, Luxturna proved its effectiveness through a phase 3 clinical trial conducted on patients with hereditary retinal disease in whom biallelic mutations in the RPE65 gene were confirmed. Clinical results showed that at one year of treatment, functional vision treated with Luxturna was statistically significantly improved compared to the control group that did not receive treatment. As a result of evaluating the average score of the Multi-Luminance Mobility Test as the primary endpoint at a year of treatment, the score change in the Luxturna treatment group was 1.8 points, which was 1.6 points higher than the control group's score change of 0.2 points.
- Company
- Roche’s Rozlytrek lands in tertiary hospitals in Korea
- by Eo, Yun-Ho Sep 25, 2023 05:34am
- The tumor-agnostic anticancer drug ‘Rozlytrek’ may now be prescribed in 5 tertiary hospitals in Korea. According to industry sources, Roche Korea’s NTRK(Neurotrophic tyrosine receptor kinase) inhibitor Rozlytrek (entrectinib)’ has passed review of drug committees (DCs) at the Big 5 tertiary hospitals in Korea, - Samsung Medical Center, Seoul National University Hospital, Seoul, Asan Medical Center, Seoul St.Mary’s Hospital, and Sinchon Severance Hospital – and its prescription code has been inserted in medical institutions nationwide. Rozlytrek was listed for reimbursement this April. It is currently reimbursed for first-line or higher treatment of adult and pediatric patients 12 years of age and older with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation, whose cancer type is classified as Type 2A or higher under the NCCN guidelines and are locally advanced, metastatic or have high risk of severe morbidity upon surgical resection, and have progressed following the use of existing treatments (or therapies) and have no other available treatment options. The drug was approved in April 2020 as a treatment for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation and for adult patients with locally advanced ROS1-positive or metastatic NSCLC. Rozlytrek was approved based on the Phase I/II STARTRK-NG trial on pediatric patients, as well as the pivotal Phase II STARTRK-2 and Phase I STARTRK-1 and ALKA-372-001 trials. In the Phase II STARTRK-2 study, Rozlytrek shrank tumors in more than half (objective response rate [ORR] = 56.9%) of people with NTRK fusion-positive solid tumors. Objective responses to Rozlytrek were seen across 10 different solid tumor types with a median duration of response [DoR] = 10.4 months. Treatment of CNS metastatic conditions in patients with NTRK gene fusion-positive cancer had been limited until now because most anticancer drugs have not been able to pass through the blood-brain barrier (BBB), rendering it difficult for the drugs to be exposed to the central nervous system (CNS) to an appropriate level However, Rozlytrek showed an ORR of 62.5% even in the 16 patients with CNS metastasis at baseline, showing a consistent response rate regardless of CNS metastasis. This is because Rozlytrek is designed to permeate the BBB partially remain within the CNS and act on primary brain tumors and brain metastases.
- Company
- RET-targeted anticancer drugs fail reimb…no promise
- by Eo, Yun-Ho Sep 25, 2023 05:34am
- With RET-targeted anticancer drugs failing to receive reimbursement, patients are now left to wait indefinitely for coverage of their drugs. Lilly Korea's RET inhibitor Retevmo (selpercatinib) failed to be listed for reimbursement last month due to the final breakdown in drug price negotiations with the National Health Insurance Service. This drug was the first treatment option for patients with RET gene mutated non-small cell lung cancer and thyroid cancer and was the only drug that continued on evaluations for reimbursement in Korea. Only two RET-targeted therapies – Retevmo and Gavreto – are currently approved in Korea. In the case of Gavreto, the Health Insurance Review and Assessment Service’s Cancer Disease Deliberation Committee and the Drug Reimbursement Evaluation Committee determined the drug inadequate for reimbursement and made a final ‘non-reimbursement’ decision. Only Retevmo passed the DREC meeting Before Retevmo, no other option had been available for RET-mutated NSCLC or thyroid cancer in Korea. This is why the Ministry of Food and Drug Safety had approved Retevmo for the treatment of: ▲adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC); ▲adults and pediatric patients 12 years of age or older with advanced or metastatic RET-mutated medullary thyroid cancer who require systemic therapy; and ▲ adult patients who are refractory to radioactive iodine therapy and who have prior sorafenib and/or lenvatinib treatment, with advanced or metastatic RET-fusion benign thyroid cancer who require systemic therapy. The company had attempted to receive reimbursement for the thyroid cancer and NSCLC indications. In other words, Retevmo was accepted as a drug that requires urgent introduction in recognition of its innovation and clinical value in Korea. In fact, among the A7 countries that are used as Korea’s drug price reference countries, Retevmo is covered and used in 6 countries (US, Germany, Italy, UK, Switzerland, Japan) other than France. This was why Retevmo had applied for expedited reimbursement listing through the approval-evaluation linkage system and engaged in discussions with the relevant authorities for a year and a half but to no avail. Although the authorities acknowledged the innovativeness of the drug, they deemed that there remained uncertainty about the efficacy of the specific gene-targeting drug as it was approved through a single-arm study without a comparator rather than a Phase II trial. The MFDS has been operating an expedited review system to promptly launch and supply highly innovative drugs for life-threatening or serious conditions to the market and patients. However, only 1 out of 23 approved through the fast track is currently being covered by insurance. This means that even after the drugs receive approval quickly through fast-track review, it is difficult for cancer patients to receive treatment benefits without reimbursement. This is why non-small cell lung cancer and thyroid cancer specialists who have been longing for Retevmo’s listing are expressing the most disappointment. Se-Hoon Lee, Professor of Hematology-Oncology at Samsung Medical Center, said, “Retevmo is recommended as a first-line treatment for patients with RET fusion-positive NSCLC in the NCCN guidelines. It is very unfortunate that our patients have no opportunity to receive the proven therapeutic benefits of Retevmo.” Dong-Jun Lim, Professor of Endocrinology and Metabolism at the Catholic University of Korea Seoul St.Mary’s Hospital, said, “Although thyroid cancer is generally known to be an easy-to-treat cancer with a high survival rate, patients with medullary thyroid cancer with RET mutations have a poor prognosis and low survival rate. It is a very difficult situation for both the patients and doctors, being unable to use treatments with proven, significant clinical results on patients with RET-mutated medullary thyroid cancer due to the lack of treatment access, or in other words, coverage.”
- Company
- Boryung develops 4-drug kanarb combo… increases lineup
- by Chon, Seung-Hyun Sep 22, 2023 05:42am
- Pic of Kanarb Family On the 20th, Boryung Pharmaceutical announced that the Ministry of Food and Drug Safety has approved the Phase III clinical trial plan (investigational new drug, IND) for ‘BR1018,’ its incrementally modified drug candidate for hypertension and dyslipidemia. BR1018 is a four-drug combination that combined amlodipine, atorvastatin, and ezetimibe with fimasartan. Fimasartan is the main active ingredient of Kanarb, a new hypertension drug developed by Boryung. Kanarb was released in 2011 as a new drug for high blood pressure in the angiotensin II receptor blocker (ARB) class and was developed by Boryung with its proprietary technology. Amlodipine is a calcium channel blocker (CCB) type hypertension treatment drug. Atorvastatin and ezetimibe are treatments for hyperlipidemia. The clinical trial for BR1018 will test the drug’s efficacy on 156 patients with essential hypertension and primary hypercholesterolemia for 2 years. The company explained, “As the drug contains 4 ingredients in a single pill, we expect it may improve the patient’s medication compliance.” By releasing a series of combination drugs that use its Kanarb, Boryung has provided various treatment options in the field. In 2013, the company released LaCor, which was a combination of Kanarb and the diuretic hydrochlorothiazide. In 2016, the company introduced Tuvero, a combination of Dukarb (Kanarb+calcium channel blocker (CCB) drug amlodipine) and rosuvastatin, a hyperlipidemia treatment drug. In 2019, the company launched Dukaro, a 3-drug combination drug that combined rosuvastatin with Dukarb, and Akarb, a combination of Kanarb and atorvastatin, for hypertension and hyperlipidemia. In June last year, it released Dukarb Plus, a combination of Kanarb with amlodipine and hydrochlorothiazide. Last year, the Kanarb family recorded prescription sales of KRW 141.8 billion. Its sales have continued to grow at an average rate of more than 23% over the past 5 years. Boryung secured 131 papers and over 72,000 clinical cases related to Kanarb, added an indication for reducing proteinuria, and expanded the age of use. It also demonstrated its effect in controlling blood pressure in stroke patients and reducing stroke recurrence. Boryung plans to continue launching combination drugs and expand clinical research to achieve annual sales of KRW 200 billion by 2026 through the ‘Great Kanarb’ strategy. Currently, Boryung is developing additional Kanarb fixed-dose combinations including BR1015, a combination drug for high blood pressure, and BR1017, a combination drug for hypertension and dyslipidemia. The company had also applied for IND for BR1019, a combination drug that can simultaneously treat high blood pressure and diabetes. Jong-Rae Lim, Head of R&D at Boryung said, “We aim to provide various treatment options to prescribing doctors through continuous development of Kanarb combinations while improving patients’ medication compliance. We will enhance the clinical excellence of our Kanarb family by continuing to add indications through continuous research and investment.”
- Company
- Next-gen asthma drug Tezspire to soon be introduced to KOR
- by Eo, Yun-Ho Sep 22, 2023 05:41am
- The next-generation drug for severe asthma, ‘Tezpire' is soon expected to enter the Korean market. According to industry sources, AstraZeneca Korea has submitted an application for the approval of ‘Tezspire (tezepelumab)’ in H2 to the Ministry of Food and Drug Safety and is receiving its final review. Whether AstraZeneca will be able to continue on its lineage in the field of asthma with Tezspire after failing to list its ‘Fasenra (benralizumab)’ for reimbursement remains to be seen. As a viable competitor to Sanofi’s ‘Dupixent (dupilumab),’ Tezspire inhibits the action of the thymic stromal lymphopoietin (TSLP), a key epithelial cytokine that sits at the top of multiple inflammatory cascades, to block the inflammatory chain reaction. The drug was approved by the US FDA in 2021 as a treatment for adult and pediatric patients aged 12 years and older with severe asthma., and added a self-injection formulation to its approval in February this year. Tezspire demonstrated a consistent and significant reduction in asthma exacerbation in the Phase II PATHWAY trial and Phase III NAVIGATOR trial, which included a broad population of severe asthma patients irrespective of key biomarkers, including blood eosinophil counts, allergic status, and fractional exhaled nitric oxide (FeNO). In the study, the most common adverse reactions shown in patients who received Tezspire were pharyngitis, rash, arthralgia, and injection site reactions. The findings from the NAVIGATOR study were published in The New England Journal of Medicine in May 2021. The Korea National Enterprise for Clinical Trials had designated Tezspire as the No.1 drug in need of urgent introduction to Korea in its report on the ‘List of foreign new unintroduced drugs that should be promptly Introduced to Korea.’
- Company
- A new drug for optic shylomyelitis is necessary
- by Eo, Yun-Ho Sep 20, 2023 05:35am
- Professor Kim, Ji-eun Off labels refer to the act of prescribing a medicine for an indication other than a use approved by the Ministry of Food and Drug Safety. In general, the use of the drug has been determined by the health authorities, and the question may arise as to why it is necessary. However, there is an area of disease where this Off label prescription is covered by insurance benefits. It is NMOSD. Currently, the immunosuppressant Azathioprine is used for primary maintenance treatment for optic vesical schomyelitis, and Mycophenolate or Mapthera are prescribed as the second treatment after the failure of Azachioprine treatment. Mycophenolate and Rituximab Offlabel drugs that do not have indications for optic nerve lingualism. The cause is simple.These drugs did not formally obtain indications through clinical studies of optic severe, but were confirmed to be effective through presumed efficacy and long-term accumulated prescription experience. However, there is a more bizarre situation in the area of optic sever. Immediately through phase 3 clinical trials, its effectiveness is confirmed, and officially approved new drugs are not eligible. Dailypharm met with Kim Ji-eun, the insurance director of the Korean Neurological Society (Professor of Neurology at Eo University Seoul Hospital), and heard about the current treatment environment of optic scurveitis and the need for new drugs. The drug used in the treatment of the optic sbellomyelitis category is known as an off label drug. I wonder if there are any side effects to the use of these drugs, and what their characteristics are. Of course, it must be the necessary medicines. However, as it is not a drug that has been proven to be effective and safe in the disease based on systematic clinical research, there are concerns in terms of side effects and effects. In particular, there are many reports that the primary treatment, Azathioprine, is low compared to other drugs, along with the risk of side effects such as bone marrow suppression, elevated liver levels, and increased cancer incidence during long-term use. In fact, about 50% of patients who used Azathioprine stopped treatment due to side effects within 18 months of treatment, of which 15% were due to lack of effects such as recurrence, and 62% were due to side effects of the drug. When following the current domestic benefit standards, Rituximab is used as a tertiary drug if there is a recurrence in the primary and secondary drugs. In the case of Rituximab, it is off label, but compared to other drugs, it has a better recurrence effect, and it is excellent in terms of effectiveness and safety, so in some patients with severe severity, it is increasingly skipping the first and second drug and administering it right away. In some countries abroad, Rituximab can be used as a primary treatment. The effect of Rituximab is not bad, but do we still need a new drug? It's excellent compared to existing drugs. There are patients who still have a relapse even after using Rituximab, so a new drug is needed for them. It is reported that about 10% of patients experience recurrence even after using Rituximab and as the accessibility of new drugs is reduced, these patients have no choice but to maintain their existing treatment even after recurrence. New drugs include monoclonal antibodies that directly act on the main inflammatory immune response targets of optic spondylomyelitis pathology, such as Soliris, Enspring and Uprizuna. Some of them are currently in the process of applying their benefit. Eculizumab is a prote suppressant, and Enspryngg is an interleukin-6 resuppressant with other mechanisms, so that patients who have recurrent in existing drugs can have the opportunity for treatment without being marginalized. In particular, these new drugs are very effective against conventional drugs, and in the case of ekulizumab, it has been found to reduce the risk of recurrence by 94%. - Among the drugs to be said, Soliris and Enspryngg are going through the process. However, there is a disagreement between the pharmaceutical company and the government over the standard, so I know it is not easy to discuss. After prescribing all the drugs that can be used now, it is the direction to recognize the benefit only at the back end (4th or more). The desperate thing for the medical staff is to first offer a new treatment option to patients who don't have a treatment option, and then the best treatment option to prevent irreversible recurrence. However, new drugs are somewhat expensive, and considering the social costs, I think that even patients who have failed to treat ritukshimab need urgent benefits. -As the drug price is high and the non-reimbursed status continues, the expiration date of the drug's PMS is getting closer. If the PMS is not completed under the regulations, the permit will be withdrawn. These new drugs are not enough to come in or not to come in. It was a disease that had not been diagnosed before, but it became possible to diagnose it through anti-quaporin-4 antibody tests, etc., and treatment that can reduce the disorder through drugs became possible. I hope that access to drugs will improve as soon as possible so that patients in need can receive treatment. Have you ever given an opinion to the government at the society level? The conference has also submitted several submissions of opinions on new drugs so that alternative options can be quickly arranged, and it continues to be of interest. I hope the benefit will be made quickly so that even a small number of patients can provide treatment options to those who really need it. Also, the disease itself has a very big impact on the patient's life. In addition, we hope that various new drugs targeting various mechanisms will be available in clinical practice as soon as possible so that an environment where customized treatment can be created for patients can be created.
- Company
- Pricing & reimbursement specialist introduced as a new job
- by Kang, Shin-Kook Sep 20, 2023 05:35am
- New occupations such as ‘Pricing & reimbursement specialist’ and ‘biopharmaceutical candidate substance researcher’ were added as new occupations in the bio and pharmaceutical industry. On the 19th, the Korea Employment Information Service (President Young-Jun Kim) announced it had added 156 new occupations in the fields of life sciences, chemistry, energy and environment, construction, agriculture, forestry, and fisheries that emerged as new occupations due to factors such as the development of medical technology to accommodate the aging population and the integration of Intelligent information Technology, into the Korean Dictionary of Occupation. First, a Pricing & reimbursement specialist was introduced as a new job. In the dictionary, pricing & reimbursement specialist is defined as one who sets the price of new drugs that will be sold on the market and has the role of negotiating drug prices for new prescription drugs with the health authorities. A clinical data manager manages and supports clinical data for the overall progress of the clinical trial, including clinical data management plan development, database structure development, data entry, inconsistent data checking, logical error checking, medical coding, and data locking. Also, the patient safety & quality coordinator was listed as a new occupation. The patient safety & quality coordinator performs tasks related to patient safety and medical quality improvement in medical institutions and performs a series of patient safety activities to prevent and manage patient safety-related accidents. Also, ▲ Biopharmaceutical candidate substance researcher and ▲ Biopharmaceutical process development researcher were newly listed, due to increased new investment in new biopharmaceutical development such as cell therapy products, boosting the biopharmaceutical industry and incorporating data-based artificial intelligence technology. In addition, ▲Biopharmaceutical clinical/non-clinical researcher ▲Biopharmaceutical quality assurance technician ▲Biopharmaceutical quality tester ▲Biochemical strain management researcher ▲Biochemical product culture researcher ▲Biopharmaceutical culture researcher ▲Biopharmaceutical isolation and purification manager were added as new occupations. .Also, in addition to the ▲advanced life-sustaining treatment directive counselors, which have risen as an issue due to the rise of the super-aging society, ▲self-reliance support managers, and ▲consumer financial protection experts who support youth independence and the rights of financial consumers, were newly listed .Joong-Jin Kim, a researcher at the Korea Employment Information Service, said, “Digital information technologies such as data-based artificial intelligence, the Internet of Things, and Digital Twins are driving changes in the world of work by being applied to all industries, including life, construction, and agriculture .New occupations have been appearing in line with the establishment of various legislations to support the happy and safe life of the public, so it is necessary to pay attention to these jobs in terms of career preparation.” Meanwhile, the Employment Information Service has been systematically researching and analyzing the rapidly changing occupation world and publishing the Korean Dictionary of Occupation to support people's career choices and utilize it in the government's job policy .Newly registered occupations according to the survey can be searched in the 'Korean Dictionary of Occupation’ under the 'Vocational Path’ menu at Worknet (www.work.go.kr).
- Company
- No news after passing the cancer screening
- by Eo, Yun-Ho Sep 20, 2023 05:35am
- Xospata's progress in expanding insurance benefits, which seemed to be going smoothly, appears to have stopped. According to related industries, Astellas Korea Pharmaceutical's FLT3 mutation-positive recurrence or Acute Myeloid Leukemia treatment Xospata was not submitted during the three HIRA Pharmaceutical Reimbursement Evaluation Committee meetings held from July to September. Expectations were high when an application for benefit expansion was submitted in February and passed the Cancer Disease Review Committee in May, but it is believed that differences of opinion regarding finances arose during the subsequent procedures. As Xospata is a PE-exempt drug, the NHIS drug price negotiation process must be completed in case of expanded coverage. Therefore, the application of benefit expansion can be assessed depending on whether it is submitted to the committee in the future and when it is passed. This drug has been approved as monotherapy for patients with FLT3 mutation-positive relapse or Acute Myeloid Leukemia, but the current reimbursement standard only allows up to 4 cycles for patients eligible for allogeneic hematopoietic stem cell transplantation. Aside from financial issues, there are no specific reasons to limit the dosing cycle of Xospata. Looking at the ADMIRAL clinical study of this drug, it was designed with no limitation on the administration period, and the NCCN guidelines also recommend it as 'Category 1' with no limitation on the period. Currently, the best treatment for patients with Acute Myeloid Leukemia is hematopoietic stem cell transplantation, but the risk of recurrence is high and many patients are elderly, making transplantation difficult. However, for patients who cannot undergo hematopoietic stem cell transplantation and who are excluded from the current reimbursement standards, there is no suitable treatment alternative other than Xospata, so they are currently stuck with chemotherapy developed 40 years ago. Xospata is a drug that targets both FLT3 mutations, which are divided into two mutation types, FLT3-ITD and FLT3-TKD. As a monotherapy that is taken orally once a day, it is possible to self-medicate at home without frequent hospital visits, and clinical trials have shown higher effectiveness and safety compared to existing chemotherapy.
- Company
- Korea United Pharm signs export agreement with Vietnam TAK
- by Nho, Byung Chul Sep 19, 2023 05:42am
- From the left, Won-Ho Kang, co-CEO of Korea United Pharm, and Thi Tuyet Nga, CEO of Thanh An Khang Pharmaceutical On the 18th, Korea United Pharm (CEO Duk-Young Kang) attended the 2023 Global Bio& Pharma Plaza (GBPP) 2023 and forged close relationships with over 20 overseas buyers. The company announced that it had accelerated its global expansion by signing export contracts for Vietnam and the Philippines on the day of the event. Korea United Pharm attended the GBPP 2023 event on the 14th as one of the major companies carrying out various global business projects in Korea, such as the export voucher business overseas branching businesses, and the Medi-star Initiative with KOTRA. Duk-Young Kang, CEO of Korea United Pharm also attended the preliminary VIP meeting that was held before the contract signing ceremony and shared ideas on global cooperation with key members of the event, including Yong-Pil Lee, Director-General for High Technology Industry, Jeong-Yeol Yu, President of KOTRA, and Seung Ryel Baek, Chairman of Korea Pharmaceutical Traders Association, and expressed the company’s determination to expand its reach in the global market. On this day, Korea United Pharm held an export contract signing ceremony with Vietnam and the Philippines. Specifically, the company signed a contract with Vietnam's Thanh An Khang Pharmaceutical (hereinafter referred to as TAK) to export Newbutin SR Tab among others, and plans to actively target the relevant local market together with TAK, which has strengths in the area of digestives in Vietnam. In addition, the company signed a contract with One Pharma in the Philippines to export Cilostan CR Tab and Clanza CR Tab, thereby laying the foundation for the entry of IMDs into the Philippines. In addition, Korea United Pharm set up a booth at the event to discuss local expansion and export opportunities with 20 overseas buyers and established a close cooperation system. Won-Ho Kang, co-CEO of Korea United Pharm, said, “We plan to strengthen our product competitiveness through continuous R&D and innovation to accelerate our entry into ASEAN, Central and South America, and the Middle East, and seek ways to enter major countries such as the U.S. and Europe.” GBPP is a global business event held by the Ministry of Trade, Industry and Energy, KOTRA, and the Korea Pharmaceutical Traders Association to support the export of Korean pharmaceutical and bio companies. About 100 buyers from 31 countries around the world, including the United States, India, and Brazil, participated in the event and forged export cooperation relationships with domestic companies.
